Cargando…
Study on the infusion-site adverse events and vascular distribution of epirubicin in chemotherapy with epirubicin and fosaprepitant
In breast cancer patients on a fluorouracil-epirubicin (EPI)-cyclophosphamide (FEC) regimen and intravenous fosaprepitant (FAP) during chemotherapy, infusion-site adverse events such as vascular pain and induration and/or phlebitis are observed. In the present study, adverse events induced by the FE...
Autores principales: | Yamasaki, Miho, Kimura, Ryuji, Mayahara, Shigeri, Maeda, Yorinobu, Takahashi, Mamoru, Nishida, Toshihiro, Oda, Keisuke, Murakami, Teruo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535639/ https://www.ncbi.nlm.nih.gov/pubmed/31289676 http://dx.doi.org/10.3892/mco.2019.1849 |
Ejemplares similares
-
Study on the method to avoid infusion-site adverse events following chemotherapeutic treatment with epirubicin and fosaprepitant using immortalized human umbilical vein endothelial cells
por: Yamasaki, Miho, et al.
Publicado: (2022) -
Epirubicin
por: Cornish, J., et al.
Publicado: (1988) -
Delivery of epirubicin via slow infusion as a strategy to mitigate chemotherapy-induced cardiotoxicity
por: Yang, Fang, et al.
Publicado: (2017) -
Local Efficacy and Safety of Transarterial Chemoembolization for Hepatocellular Carcinoma: Epirubicin-Loaded DC Beads vs. Epirubicin-Lipiodol Emulsion with Gelatin Sponge (cTACE)
por: Ono, Yusuke, et al.
Publicado: (2021) -
Epirubicin-induced Kounis syndrome
por: Liang, Hui-zhu, et al.
Publicado: (2021)